The most unexpected number in the first detailed clinical account of a Bundibugyo virus patient is not the survival. It is where the virus was concentrated.
On day five of illness, an oropharyngeal swab from a 39-year-old American healthcare worker evacuated from the Democratic Republic of the Congo carried roughly 9 x 10⁷ copies of viral RNA per milliliter. His plasma that same day carried about 7 x 10⁶. More than a tenfold difference, with the throat, not the bloodstream, holding the larger load.
The authors flag this directly. Viral concentrations across body compartments differed from previous reports in patients with Ebola virus disease, they write, most notably «the comparatively high concentrations in oropharyngeal swabs.»The case was published in Nature Medicine by a team at Charité Universitätsmedizin Berlin with collaborators at the CDC, the U.S. Department of State, the Robert Koch Institute, Emory University, and Congo’s Institut National de Recherche Biomédicale.
Two Procedures, Then Nine Days of Nothing
The patient’s exposure history is a study in how invisible transmission can be. Nine days before symptoms began, he performed an ultrasound examination. Eight days before, he operated on a 14-week pregnant woman who had presented with threatened miscarriage and suspected cholecystitis, and who later developed severe hemorrhagic manifestations and died. The same day, he performed a colonoscopy on a man with rectal bleeding who died shortly afterward.
Standard personal protective equipment was used for both procedures. He recalled no specific high-risk exposure. Several other healthcare workers and family caregivers later developed similar hemorrhagic illness and died.
He began with severe muscle pain and malaise, entered voluntary self-isolation the same day, and developed a fever of 38.9 degrees Celsius the following day despite acetaminophen. A pan-Ebola PCR on plasma came back positive on day two. By day three, he had abdominal pain, vomiting, confusion, and orthostatic symptoms.
A Treatment Authorized at 12:45 in the Morning
There is no approved vaccine or drug for Bundibugyo virus. The two licensed Ebola vaccines target the Zaire species, and this patient had in fact received a single dose of rVSV-ZEBOV 41 months earlier, against an antigenically distinct virus.
Emergency access to MBP134, an investigational cocktail of two broadly neutralizing monoclonal antibodies, was initiated on day three through Mapp Biopharmaceutical, the FDA, and the Administration for Strategic Preparedness and Response. Authorization under an emergency investigational new drug application was granted at 00:45 Central Africa Time on day four.
The 50 mg per kilogram dose was administered that evening during a layover and crew change on the medical evacuation flight, which was routed through Bunia and Entebbe and operated a modified Gulfstream fitted with a negative-pressure containment system. A 200 mg loading dose of remdesivir was given off-label. He was still vomiting through the infusion.
He arrived at Berlin’s high-level isolation unit on day five with thrombocytopenia, lymphopenia, and elevated liver enzymes. Care teams worked in three-hour bedside shifts in fully enclosed suits. Five family members classified as high-risk contacts were quarantined in a separate section of the unit and are described in a companion paper on post-exposure prophylaxis published the same day.
Viral RNA Cleared, but Semen Lagged
Transaminases kept climbing until day eight, peaking at 635 and 773 units per liter, prompting a one-day pause in remdesivir before they declined. Bilirubin stayed normal. From day seven, he was afebrile without antipyretics.
Viral RNA fell below the limit of detection in plasma, throat swabs, urine, and stool by day 13. Semen still contained roughly 2.5 x 10³ copies per milliliter on day 20 and tested negative on day 25. Three specialized laboratories attempted to culture live virus from throat swabs, plasma, and semen and failed in every attempt, though the authors note this cannot be attributed to the antibody treatment without pre-treatment culture data.
He was discharged on day 22 after symptom onset. Sequencing showed 99.96 percent nucleotide identity to the current outbreak lineage and clear separation from the 2007 Ugandan and 2012 Congolese outbreaks, consistent with a new introduction into humans.
The authors also report that his own immune system mounted a response. Because the antibodies in MBP134 do not bind the secreted glycoprotein, the team measured antibodies against that target and found levels rising between days five and six, along with virus-specific IgM and IgA. Monoclonal antibody therapy has been associated with reduced endogenous antibody production in Ebola survivors, so the preservation of humoral immunity here is notable.
The Outbreak This Case Sits Inside
The single most important limitation is the obvious one. This is one patient, treated with two agents plus intensive supportive care in a European isolation unit, and the report is an accepted manuscript still awaiting final editing. Nothing here establishes that MBP134, remdesivir, or the combination works. The authors state that larger clinical studies are needed.
That context matters because the outbreak is enormous. Congo’s health ministry declared the outbreak in Ituri Province on May 15, 2026, and the WHO declared a public health emergency of international concern two days later. As of data through August 22, 2026, the European Center for Disease Prevention and Control reported 5,514 confirmed cases and 2,642 deaths in Congo, with Ituri Province accounting for 4,607 cases and 2,065 deaths. The WHO has described it as the largest Ebola outbreak ever reported in the country and one expanding faster than any previous Ebola outbreak, now spread across six provinces. Uganda, which reported a small number of travel-linked cases, declared its own outbreak over in late July.
CDC has assessed the risk to the American public as low, and no cases have been confirmed on U.S. soil. Its health advisory asks clinicians to consider Ebola disease in patients with compatible symptoms and recent travel to affected areas.
If the throat finding holds up in larger series, it could carry practical weight for how healthcare workers are protected during airway and endoscopic procedures. One patient cannot establish that. It can point researchers to the question.
Key Questions Answered
What is Bundibugyo virus?
One of the orthobunyavirus species that cause Ebola disease. It caused only two prior outbreaks, in Uganda in 2007 and Congo in 2012, totaling 206 confirmed cases. No vaccine or treatment is approved for it.
What was surprising about this case?
Viral RNA was more than ten times higher in throat swabs than in plasma on day five, a pattern the authors describe as differing from previous reports in patients with Ebola virus disease.
Does this prove the treatment worked?
No. This is a single patient who received two investigational or off-label agents plus intensive supportive care. The authors state that the clinical benefit of MBP134 remains unknown.
What is MBP134?
An investigational combination of two broadly neutralizing monoclonal antibodies developed by Mapp Biopharmaceutical, given here at 50 mg per kilogram under FDA emergency authorization.
How long did the virus persist?
Undetectable in blood, throat, urine, and stool by day 13. Semen was still positive at low levels on day 20 and negative by day 25.
How large is the current outbreak?
ECDC reported 5,514 confirmed cases and 2,642 deaths in Congo as of data through August 22, 2026. Figures change frequently, so check the WHO and CDC for the latest numbers.
